Morgan Stanley Pharvaris N.V. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Pharvaris N.V. stock. As of the latest transaction made, Morgan Stanley holds 59,772 shares of PHVS stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,772

Previous 75,365 20.69%

Holding current value

$1.29 Million

Previous $1.18 Million 11.16%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$11.83 - $18.66 $184,465 - $290,965	-15,593 Reduced 20.69%	59,772 $1.05 Million
Q1 2025 May 15, 2025	BUY	$14.9 - $19.54 $720,683 - $945,110	48,368 Added 179.16%	75,365 $1.18 Million
Q4 2024 Feb 14, 2025	BUY	$17.87 - $25.01 $49,071 - $68,677	2,746 Added 11.32%	26,997 $517,000
Q3 2024 May 14, 2025	BUY	$15.73 - $21.4 $15,022 - $20,437	955 Added 4.1%	24,251 $449,000
Q3 2024 Nov 14, 2024	BUY	$15.73 - $21.4 $15,022 - $20,437	955 Added 4.1%	24,251 $449,000
Q2 2024 May 14, 2025	SELL	$15.67 - $24.59 $57,994 - $91,007	-3,701 Reduced 13.71%	23,296 $437,000
Q2 2024 Oct 17, 2024	SELL	$15.67 - $24.59 $90,024 - $141,269	-5,745 Reduced 19.78%	23,296 $437,000
Q2 2024 Aug 14, 2024	SELL	$15.67 - $24.59 $90,024 - $141,269	-5,745 Reduced 19.78%	23,296 $437,000
Q1 2024 Oct 17, 2024	BUY	$21.26 - $32.07 $122,138 - $184,242	5,745 Added 24.66%	29,041 $671,000
Q1 2024 Aug 16, 2024	BUY	$21.26 - $32.07 $139,316 - $210,154	6,553 Added 29.14%	29,041 $671,000
Q1 2024 May 15, 2024	BUY	$21.26 - $32.07 $139,316 - $210,154	6,553 Added 29.14%	29,041 $671,000
Q4 2023 Aug 16, 2024	SELL	$15.2 - $28.05 $12,281 - $22,664	-808 Reduced 3.47%	22,488 $630,000
Q4 2023 Feb 13, 2024	SELL	$15.2 - $28.05 $170,376 - $314,412	-11,209 Reduced 33.26%	22,488 $630,000
Q3 2023 Nov 15, 2023	SELL	$14.68 - $21.4 $170,801 - $248,988	-11,635 Reduced 25.67%	33,697 $703,000
Q2 2023 Aug 14, 2023	SELL	$7.82 - $16.0 $28,566 - $58,448	-3,653 Reduced 7.46%	45,332 $686,000
Q1 2023 May 15, 2023	BUY	$6.34 - $12.27 $68,503 - $132,577	10,805 Added 28.3%	48,985 $394,000
Q4 2022 Feb 14, 2023	BUY	$1.98 - $11.46 $37,788 - $218,714	19,085 Added 99.95%	38,180 $429,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $25.8 $17,479 - $58,798	2,279 Added 13.55%	19,095 $146,000
Q2 2022 Oct 27, 2022	BUY	$16.35 - $27.5 $10,316 - $17,352	631 Added 3.9%	16,816 $372,000
Q2 2022 Aug 15, 2022	BUY	$16.35 - $27.5 $10,316 - $17,352	631 Added 3.9%	16,816 $372,000
Q1 2022 Oct 27, 2022	SELL	$15.98 - $19.65 $10,083 - $12,399	-631 Reduced 3.75%	16,185 $294,000
Q1 2022 May 13, 2022	SELL	$15.98 - $19.65 $33,094 - $40,695	-2,071 Reduced 11.34%	16,185 $294,000
Q4 2021 Feb 14, 2022	BUY	$13.28 - $18.0 $9,415 - $12,762	709 Added 4.04%	18,256 $262,000
Q3 2021 Nov 15, 2021	BUY	$13.14 - $20.97 $230,567 - $367,960	17,547 New	17,547 $311,000

Others Institutions Holding PHVS

# of Institutions

Shares Held

39.2M

Call Options Held

Put Options Held

View Full List

About Pharvaris N.V.

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $731M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

More about PHVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account